Entrada Therapeutics, Inc. Common Stock(TRDA)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$7.09
52-Week Range
$4.93 – $16.45
YTD
-29.45%
IV Rank (30D)
15.87
Straddle Price
$4.45
P/C Vol Ratio
0.00
Market Cap
$0.3B
Fair Value
-1.4% vs price
Confidence: 13% Alpha Score: 0.01

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.47%
Beta vs SPY1.00
Cost of Equity (CAPM)9.22% (VRP-adj)
WACC9.24%
Volatility Risk Premium-75.8pp (IV − HV30), ERP adj -25bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-61.3%
Book / Price95.8% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-2296.3%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$9.63 (Market Anchor value)
SMA 20 / Bollinger Mid$6.54
Bollinger Width / SMA20268.4% (drives anchor stability)
Net Debt$-0.1B
Market Cap$0B
Peers used for multiples: BIIB, REGN, UTHR (filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$6.99
Current Price
$7.09
Deviation
-1.4%
Forward-Return Rank LONG gates ✓
?
Horizon Expected α z Pred Blended z Rank % Active?
21d -4.8% -1.09 -0.65 2.8%
42d -6.3% -0.69 -0.45 4.5%
63d -6.2% -0.21 -0.21 8.6%
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon). For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference. flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 18.1× · 3 peers
Peer EV/EBITDA n/a 0% median 14.4× · 3 peers
Peer P/B $13.38 50% median 2.0× · 3 peers
Peer P/S $0.60 50% median 4.3× · 3 peers
Market Anchor (SMA50) $9.63 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-18 · updated 2026-06-18 20:59:30.593000
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$0.3B

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the pot…

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -12.40% 5
Feb -3.69% 5
Mar +3.94% 5
Apr -8.16% 5
May -7.93% 5
Jun +24.75% 5
Jul +4.62% 4
Aug +1.58% 4
Sep +5.03% 4
Oct +10.37% 5
Nov +6.35% 5
Dec -9.19% 5
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $6.60
SMA 50: $9.48
SMA 200: $9.44
Current: $7.09
EMA 12: $6.66
EMA 26: $7.29
MACD: -0.6294 | Signal: 0.2692
BEARISH
ADX (14): 27.04
TREND
+DI: 22.84
−DI: 25.71
Momentum Oscillators
RSI (14): 47.00
NEUTRAL
Stoch %K: 73.92
Stoch %D: 63.77
Williams %R: -7.96
Volume & Volatility
BB Upper: $7.17
BB Lower: $6.02
NEUTRAL
OBV: -2,110,312
Vol SMA 20: 282,010
Vol ROC: 44.33%
ATR: $0.60
True Range: $0.44
HV 20: 65.5%
HV 30: 256.6%
HV 60: 187.0%

Data Summary
Data Points: 500
Last Updated: 2026-06-18T21:15:12.631000
Date Range: 2024-06-21T00:00:00 – 2026-06-18T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Earnings History
8 of 9 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-13 After-Close 23.61% 0.44% 0.02x Within
2024-11-05 Pre-Market 23.07% 4.78% 0.21x Within
2025-01-15 Pre-Market 39.23% 3.52% 0.09x Within
2025-05-08 Pre-Market 60.23% 6.33% 0.11x Within
2025-08-06 After-Close 82.35% 10.92% 0.13x Within
2025-11-06 Pre-Market 70.61% 0.14% 0.00x Within
2026-01-08 Pre-Market 45.62% 1.68% 0.04x Within
2026-02-26 Pre-Market 36.67% 7.29% 0.20x Within
2026-05-07 Pre-Market 30.57% 57.58% 1.88x Exceeded
Options Activity
IV Rank (30D)
15.87
IV Rank (7D)
90.03
Avg IV
156.8%
Straddle (30D)
$4.45
Straddle (7D)
$3.03
P/C Volume
0.00
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
pts EXTREME
ATM — / Wing —
30 DTE / 10d
pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
1.71
Correlation (SPY)
24.8%
0.06
Ann. Volatility
85.7%
SPY Volatility
12.4%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
Diluted shares outstanding: 41,502,270 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

120 filers31,813,596 shares$354.93M value76.66% of float
# Filer Shares Value % of Total % of Float Period
1 BAKER BROS. ADVISORS LP 5,072,730 $64.02M 18.04% 12.22% 2026-03-31
2 5AM Venture Management, LLC 4,056,379 $51.19M 14.42% 9.77% 2026-03-31
3 BlackRock, Inc. Custodian 2,358,793 $29.77M 8.39% 5.68% 2026-03-31
4 TCG Crossover Management, LLC 2,287,500 $28.87M 8.13% 5.51% 2026-03-31
5 MPM ASSET MANAGEMENT LLC 4,381,062 $25.41M 7.16% 10.56% 2025-09-30
6 Merck & Co., Inc. 1,739,768 $21.96M 6.19% 4.19% 2026-03-31
7 VANGUARD GROUP INC Custodian 1,632,460 $16.78M 4.73% 3.93% 2025-12-31
8 WELLINGTON MANAGEMENT GROUP LLP Custodian 1,034,782 $13.06M 3.68% 2.49% 2026-03-31
9 StepStone Group LP 761,277 $9.61M 2.71% 1.83% 2026-03-31
10 GEODE CAPITAL MANAGEMENT, LLC Custodian 667,347 $8.42M 2.37% 1.61% 2026-03-31
11 STATE STREET CORP 533,798 $6.74M 1.90% 1.29% 2026-03-31
12 MILLENNIUM MANAGEMENT LLC Custodian 519,356 $6.55M 1.85% 1.25% 2026-03-31
13 Jones Hill Capital LP 374,010 $4.72M 1.33% 0.90% 2026-03-31
14 JACOBS LEVY EQUITY MANAGEMENT, INC 333,914 $4.21M 1.19% 0.80% 2026-03-31
15 DIMENSIONAL FUND ADVISORS LP Custodian 324,471 $4.09M 1.15% 0.78% 2026-03-31
16 NORTHERN TRUST CORP Custodian 234,992 $2.97M 0.84% 0.57% 2026-03-31
17 Woodline Partners LP 215,977 $2.73M 0.77% 0.52% 2026-03-31
18 CITADEL ADVISORS LLC Custodian 215,018 $2.71M 0.76% 0.52% 2026-03-31
19 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 214,751 $2.71M 0.76% 0.52% 2026-03-31
20 GOLDMAN SACHS GROUP INC Custodian 212,780 $2.69M 0.76% 0.51% 2026-03-31
21 MORGAN STANLEY Custodian 260,251 $2.68M 0.75% 0.63% 2025-12-31
22 Lynx1 Capital Management LP 211,689 $2.67M 0.75% 0.51% 2026-03-31
23 Longaeva Partners L.P. 204,978 $2.59M 0.73% 0.49% 2026-03-31
24 RENAISSANCE TECHNOLOGIES LLC 202,084 $2.55M 0.72% 0.49% 2026-03-31
25 BNP PARIBAS FINANCIAL MARKETS Custodian 181,148 $2.29M 0.64% 0.44% 2026-03-31
1 filers$291.52K notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $291.52K 100.00% 2026-03-31
# Filer Notional Value % of Total Period
Insider Activity
Latest: 2026-06-12
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-12 Gina Chapman Director Grant (A) +19,000 opt EDGAR
2026-06-12 Maha Radhakrishnan Director Grant (A) +19,000 opt EDGAR
2026-06-12 Bernhardt G Zeiher Director Grant (A) +19,000 opt EDGAR
2026-06-12 Mary Thistle Director Grant (A) +19,000 opt EDGAR
2026-06-12 PETER S KIM Director Grant (A) +19,000 opt EDGAR
2026-06-12 KUSH PARMAR Director Grant (A) +19,000 opt EDGAR
2026-05-21 Bernhardt G Zeiher Director Buy (P) +5,000 $5.86 $29.3K EDGAR
2026-05-04 Nathan J Dowden President & COO Mixed $8.54 -$203.9K EDGAR
2026-05-04 Natarajan Sethuraman President, Research & Develop. Sell (S) −25,907 $15.39 -$398.8K EDGAR
2026-04-02 KORY JAMES WENTWORTH Chief Financial Officer Sell (S) −2,500 $12.95 -$32.4K EDGAR
2026-03-11 KORY JAMES WENTWORTH Chief Financial Officer Sell (S) −16,477 $13.01 -$214.4K EDGAR
2026-03-11 Nathan J Dowden President & COO Sell (S) −15,010 $13.04 -$195.8K EDGAR
2026-03-06 KORY JAMES WENTWORTH Chief Financial Officer Sell (S) −7,988 $12.25 -$97.9K EDGAR
2026-03-03 Dipal Doshi CEO Mixed +110,350 $11.72 -$340.6K EDGAR
2026-03-03 Natarajan Sethuraman President, Research & Develop. Mixed +44,325 $11.72 -$134.5K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
19 insiders · @ $7.09
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Baker Bros. Advisors (GP) LLC 10%+ Owner 4,541,670 $32.20M $6.54M 2 2025-11-12
2 Todd Foley Director 4,425,784 $31.38M $2.00M 3 2022-06-06
3 MPM BioVentures 2014 (B), L.P. 10%+ Owner 4,425,784 $31.38M $18.00M 1 2021-11-04
4 ANSBERT GADICKE 10%+ Owner 4,402,849 $31.22M -$9.17M 1 2024-12-12
5 MPM BioVentures 2018 LLC 10%+ Owner 4,381,062 $31.06M $3.25M 2 2024-12-12
6 5AM Partners V, LLC 10%+ Owner 4,056,379 $28.76M $13.02M 4 2025-11-18
7 ROCHE HOLDING LTD 10%+ Owner 2,495,385 $17.69M $0 1 2021-11-04
8 KUSH PARMAR Director 1,093,313 $7.75M $2.17M 10 2026-06-12
9 Redmile Group, LLC 10%+ Owner 954,420 $6.77M $60.00M 1 2021-11-04
10 Dipal Doshi CEO 526,014 $3.73M -$1.39M 40 2026-03-03
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio1.0
P/S Ratio46.1
EV/EBITDA-1.1
TTM Revenue$0.0B
TTM Net Income$-0.2B
TTM EPS$-3.99
ROE-61.3%